Novartis AG Return on Investment 2010-2022 | NVS

Current and historical return on investment (ROI) values for Novartis AG (NVS) over the last 10 years.
Novartis AG ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-06-30 $10.88B $85.24B 12.78%
2022-03-31 $12.13B $84.50B 14.51%
2021-12-31 $11.69B $90.72B 14.34%
2021-09-30 $11.59B $80.04B 14.56%
2021-06-30 $10.95B $78.96B 13.72%
2021-03-31 $9.82B $76.34B 12.35%
2020-12-31 $10.15B $82.93B 12.83%
2020-09-30 $5.58B $81.05B 7.21%
2020-06-30 $9.28B $77.84B 12.32%
2020-03-31 $9.59B $74.78B 12.99%
2019-12-31 $9.09B $75.90B 12.57%
2019-09-30 $8.63B $72.73B 10.98%
2019-06-30 $8.51B $71.87B 9.94%
2019-03-31 $8.27B $68.53B 8.95%
2018-12-31 $8.40B $101.16B 8.49%
2018-09-30 $9.11B $100.62B 9.29%
2018-06-30 $9.23B $99.66B 9.54%
2018-03-31 $9.08B $94.41B 9.55%
2017-12-31 $8.63B $97.45B 9.17%
2017-09-30 $8.01B $95.53B 8.62%
2017-06-30 $7.93B $92.98B 8.58%
2017-03-31 $7.74B $90.58B 8.47%
2016-12-31 $8.27B $92.79B 9.10%
2016-09-30 $8.49B $93.33B 9.33%
2016-06-30 $8.46B $88.81B 9.37%
2016-03-31 $8.64B $88.35B 9.49%
2015-12-31 $8.98B $93.45B 9.78%
2015-09-30 $9.65B $90.20B 10.78%
2015-06-30 $10.16B $92.13B 11.54%
2015-03-31 $11.06B $91.28B 12.88%
2014-12-31 $11.09B $84.64B 13.14%
2014-09-30 $11.23B $84.09B 13.27%
2014-06-30 $11.05B $83.39B 13.08%
2014-03-31 $10.90B $85.54B 12.99%
2013-12-31 $10.98B $85.71B 13.35%
2013-09-30 $11.20B $83.30B 13.73%
2013-06-30 $11.59B $81.24B 14.22%
2013-03-31 $11.67B $78.76B 14.46%
2012-12-31 $11.51B $83.04B 14.33%
2012-09-30 $9.89B $83.03B 12.44%
2012-06-30 $9.89B $78.00B 12.57%
2012-03-31 $10.11B $77.10B 12.72%
2011-12-31 $10.78B $79.80B 13.45%
2011-09-30 $12.15B $79.88B 14.96%
2011-06-30 $11.78B $81.02B 14.48%
2011-03-31 $11.42B $79.87B 14.57%
2010-12-31 $11.53B $84.13B 15.25%
2010-09-30 $11.70B $80.55B 16.45%
2010-06-30 $11.74B $69.05B 17.67%
2010-03-31 $11.15B $68.66B 17.38%
2009-12-31 $9.98B $66.14B 16.56%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84